

WEDNESDAY 16th JULY 2014 COMMENCING 9.30 AM

At the [Park Inn Hotel Cardiff North](#), Circle Way East,

Llanedeyrn, Cardiff, CF24 9XF

AGENDA

- | | |
|--|----------------------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0714 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1 - Full Submission
Lipegfilgrastim (Lonquex[®]) for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) | 2/AWMSG/0714
Appendices |
| 7. Appraisal 2 - Full Submission
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex[®]) for the treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy | 3/AWMSG/0714
Appendices |
| 8. Appraisal 3 - Limited Submission
Azithromycin (Zedbac[®]) for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intravenous therapy is required. Treatment of pelvic inflammatory disease due to susceptible microorganisms in patients where initial intravenous therapy is required. Consideration should be given to official guidance regarding the appropriate use of antibacterial agents | 4/AWMSG/0714
Appendices |
| 9. Polypharmacy: Guidance for Prescribing in Frail Adults | 5/AWMSG/0714
Appendix 1 |

- | | | |
|-----|--|----------------------------|
| 10. | Appraisal 4 – Full Submission
Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)
for the regular treatment of asthma in adults and adolescents aged 12 years old and older where use of a combination medicinal product (long-acting beta ₂ -agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta ₂ -agonists | 6/AWMSG/0714
Appendices |
| 11. | All Wales Guide: Pharmacotherapy for Smoking Cessation | 7/AWMSG/0714 |
| 12. | Appraisal 5 – Limited Submission
Linagliptin/metformin (Jentadueto®) for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control | 8/AWMSG/0714
Appendices |
| 13. | Appraisal 6 - Full Submission
Aripiprazole monohydrate (Abilify Maintena®) for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole | 9AWMSG/0714
Appendices |
| 14. | Report for the Minister of Health and Social Care on the Review of AWMSG’s policy for appraising Orphan and Ultra Orphan Medicines | 10/AWMSG/0714 |

Date of next meeting: Wednesday, 3rd September in Abergavenny